Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.61 Million EUR | 26.29% |
| 2022 | 6.81 Million EUR | -55.69% |
| 2021 | 15.38 Million EUR | 52.01% |
| 2020 | 10.12 Million EUR | -37.4% |
| 2019 | 16.17 Million EUR | 30.31% |
| 2018 | 12.41 Million EUR | 43.45% |
| 2017 | 8.65 Million EUR | 144.86% |
| 2016 | 3.53 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 8.55 Million EUR | 0.0% |
| 2023 Q3 | 8.61 Million EUR | 0.73% |
| 2023 Q1 | 8.55 Million EUR | 25.38% |
| 2023 FY | 8.61 Million EUR | 26.29% |
| 2023 Q4 | 8.61 Million EUR | 0.0% |
| 2022 Q1 | 12.38 Million EUR | -19.54% |
| 2022 Q2 | 12.38 Million EUR | 0.0% |
| 2022 Q3 | 6.81 Million EUR | -44.92% |
| 2022 FY | 6.81 Million EUR | -55.69% |
| 2022 Q4 | 6.81 Million EUR | 0.0% |
| 2021 Q1 | 12.9 Million EUR | 27.47% |
| 2021 FY | 15.38 Million EUR | 52.01% |
| 2021 Q4 | 15.38 Million EUR | 0.0% |
| 2021 Q3 | 15.38 Million EUR | 19.25% |
| 2021 Q2 | 12.9 Million EUR | 0.0% |
| 2020 Q4 | 10.12 Million EUR | 0.0% |
| 2020 Q3 | 10.12 Million EUR | -16.66% |
| 2020 Q1 | 28.91 Million EUR | 78.83% |
| 2020 FY | 10.12 Million EUR | -37.4% |
| 2020 Q2 | 12.14 Million EUR | -58.0% |
| 2019 Q3 | 16.17 Million EUR | 0.0% |
| 2019 Q4 | 16.17 Million EUR | 0.0% |
| 2019 FY | 16.17 Million EUR | 30.31% |
| 2019 Q1 | - EUR | 0.0% |
| 2018 FY | 12.41 Million EUR | 43.45% |
| 2017 FY | 8.65 Million EUR | 144.86% |
| 2016 FY | 3.53 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -24.595% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 93.429% |
| Adocia SA | 31.87 Million EUR | 72.978% |
| Aelis Farma SA | 13.08 Million EUR | 34.159% |
| Biophytis S.A. | 15.84 Million EUR | 45.662% |
| Advicenne S.A. | 24.37 Million EUR | 64.672% |
| genOway Société anonyme | 14.45 Million EUR | 40.441% |
| IntegraGen SA | 5.97 Million EUR | -44.018% |
| Medesis Pharma S.A. | 6.42 Million EUR | -34.014% |
| Neovacs S.A. | 3.71 Million EUR | -131.997% |
| NFL Biosciences SA | 3.62 Million EUR | -137.856% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -26.977% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -160.173% |
| Sensorion SA | 13.22 Million EUR | 34.892% |
| Theranexus Société Anonyme | 5.01 Million EUR | -71.684% |
| TME Pharma N.V. | 2.78 Million EUR | -209.228% |
| Valbiotis SA | 13.7 Million EUR | 37.175% |
| TheraVet SA | 1.48 Million EUR | -479.935% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 57.925% |
| argenx SE | 402.79 Million EUR | 97.862% |
| BioSenic S.A. | 32.26 Million EUR | 73.308% |
| Celyad Oncology SA | 9.97 Million EUR | 13.69% |
| DBV Technologies S.A. | 38.74 Million USD | 77.773% |
| Galapagos NV | 1.56 Billion EUR | 99.449% |
| Genfit S.A. | 105.92 Million EUR | 91.869% |
| GeNeuro SA | 20.13 Million EUR | 57.239% |
| Innate Pharma S.A. | 132.29 Million EUR | 93.49% |
| Inventiva S.A. | 101.59 Million EUR | 91.523% |
| MaaT Pharma SA | 22.46 Million EUR | 61.665% |
| MedinCell S.A. | 77.77 Million EUR | 88.926% |
| Nanobiotix S.A. | 95.74 Million EUR | 91.005% |
| Onward Medical N.V. | 25.69 Million EUR | 66.488% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 65.724% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 85.423% |
| Oxurion NV | 19.73 Million EUR | 56.364% |
| Pharming Group N.V. | 228.28 Million EUR | 96.228% |
| Poxel S.A. | 53.9 Million EUR | 84.023% |
| GenSight Biologics S.A. | 34.72 Million EUR | 75.201% |
| Transgene SA | 26.51 Million EUR | 67.523% |
| Financière de Tubize SA | 123.65 Million EUR | 93.035% |
| UCB SA | 6.56 Billion EUR | 99.869% |
| Valneva SE | 341.14 Million EUR | 97.476% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -89.4% |